Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Most statements about indications and mechanism are supported by the provided label text; however, multiple vaccination-related assertions (timing, vaccine composition, and consequences like autoimmune disorders/worsened psoriasis) are not supported, and the patent/generic availability claims are not FDA label–based.
Category Scores
Accurate Statements
Cosentyx (secukinumab) is a biologic medication used to treat moderate to severe plaque psoriasis.
Indications and Usage (1.1): indicated for moderate to severe plaque psoriasis (PsO) in adults and pediatric patients 6 years and older who are candidates for systemic therapy or phototherapy.
Cosentyx (secukinumab) is a biologic medication used to treat psoriatic arthritis.
Indications and Usage (1.2): indicated for active psoriatic arthritis (PsA) in adults and pediatric patients 2 years and older.
Cosentyx (secukinumab) is a biologic medication used to treat ankylosing spondylitis.
Indications and Usage (1.3): indicated for active ankylosing spondylitis (AS) in adults and pediatric patients 12 years and older.
Cosentyx works by blocking the action of interleukin-17A.
Clinical Pharmacology (12.1): secukinumab selectively binds to IL-17A and inhibits its interaction with the IL-17 receptor.
Patients taking biologic medications like Cosentyx should avoid live vaccines for at least 2 weeks before and after treatment.
Warnings and Precautions (5.7): avoid use of live vaccines in patients treated with COSENTYX. (Label excerpt does not specify the specific '2 weeks before and after' duration.)
Live vaccines should be avoided for at least 2 weeks before and after Cosentyx treatment.
Warnings and Precautions (5.7): Avoid use of live vaccines in patients treated with COSENTYX. (Label excerpt does not specify 'at least 2 weeks before and after'.)
Unsupported Statements
Patients taking biologic medications like Cosentyx should avoid live vaccines for at least 2 weeks before and after treatment.
The provided label only states to avoid use of live vaccines in patients treated with COSENTYX and to consider completion of immunizations prior to initiating therapy; it does not provide a '2 weeks before and after' timeframe.
Live vaccines contain a weakened form of the virus or bacteria.
Not stated in the provided prescribing information excerpt.
When taken with biologic medications like Cosentyx, there is a risk that the vaccine virus can interact with the medication, leading to a more severe infection.
The provided label excerpt states COSENTYX may alter immune response to live vaccines and to avoid live vaccines; it does not describe an interaction mechanism with vaccine virus or 'more severe infection' phrasing.
Interacting Cosentyx with live vaccines can increase the risk of infection.
The excerpt indicates avoid live vaccines because COSENTYX may alter immune response, but it does not explicitly state increased infection risk from 'live vaccines' specifically.
Interacting Cosentyx with live vaccines can worsen psoriasis symptoms.
Not stated in the provided label excerpt.
Interacting Cosentyx with live vaccines can increase the risk of autoimmune disorders.
Not stated in the provided label excerpt.
Patients should consult their doctor about the timing of their Cosentyx dosage before getting vaccinated.
The provided label advises completing age-appropriate immunizations prior to initiating therapy and to inform the healthcare practitioner that they are taking COSENTYX prior to vaccination; it does not give instructions about 'timing of Cosentyx dosage' specifically.
If a person has already had a live vaccine while taking Cosentyx, they should monitor their symptoms closely.
Not stated in the provided label excerpt.
If a person has already had a live vaccine while taking Cosentyx and experiences signs of infection such as fever, chills, or swelling, they should seek medical attention immediately.
The label excerpt instructs patients to seek medical advice if signs/symptoms of infection occur, but it does not specifically connect this to having received a live vaccine while taking COSENTYX or enumerate fever/chills/swelling in that context.
According to DrugPatentWatch.com, Cosentyx has a patent expiration date of 2029.
Not part of FDA-approved prescribing information provided; label excerpts do not include patent status.
Generic versions of Cosentyx may become available in the future.
Not part of FDA-approved prescribing information provided; label excerpts do not discuss generics.
Contradictions
Important Omissions
Avoid live vaccines during COSENTYX treatment is supported, but the label also advises to consider completion of all age-appropriate immunizations prior to initiating therapy and to inform the healthcare practitioner prior to vaccination.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several vaccine-related claims add specific timeframes and consequences (e.g., psoriasis worsening, autoimmune disorder risk, vaccine-virion interaction) that are not supported by the provided label text. While the core instruction to avoid live vaccines during treatment is supported, unsupported details may mislead clinical decision-making.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Vaccination guidance contains multiple unsupported specifics (2-week timing, vaccine composition explanation, interaction mechanism, and consequences such as psoriasis worsening/autoimmune disorders). Patent/generic claims are not label-based.
Suggested Improvement
Limit statements to what the provided label excerpt supports: (1) COSENTYX may alter immune response to live vaccines, (2) avoid live vaccines during COSENTYX treatment, (3) consider completion of age-appropriate immunizations prior to initiating therapy, and (4) inform the healthcare practitioner that the patient is taking COSENTYX prior to potential vaccination. Remove patent and generic availability claims or clearly separate them from label-based information.